Ads
related to: management of treatment resistant depression challenges and strategies pdf- Still Depressed On Rx?
Your Antidepressant May Only Be
Partially Working. Learn More.
- Patient Tools & Resources
Get Helpful Tools
And Resources.
- Doctor Conversation Guide
Ready To Talk To Your Doctor About
Your Symptoms? Download The Guide
- Download Savings Card
Download Your Savings Card Today
for an Rx MDD Treatment.
- Still Depressed On Rx?
Search results
Results From The WOW.Com Content Network
Some people who are diagnosed with treatment-resistant depression may have an underlying undiagnosed health condition that is causing or contributing to their depression. Endocrine disorders like hypothyroidism , Cushing's disease , and Addison's disease are among the most commonly identified as contributing to depression .
Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices. Depression is a symptom of some physical diseases; a side effect of some drugs and medical treatments; and a symptom of some mood disorders such as major depressive disorder ...
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) was a collaborative study on the treatment of depression, funded by the National Institute of Mental Health. Its main focus was on the treatment of depression in patients where the first prescribed antidepressant proved inadequate.
In the immediate aftermath of a high-profile suicide of a beloved celebrity like Naomi Judd, calls to suicide-prevention hotlines tend to increase.
A wide range of intervention strategies exist and they are directed towards various types of issues. Most generally, it means any activities used to modify behavior, emotional state, or feelings. [ citation needed ] Psychological interventions have many different applications and the most common use is for the treatment of mental disorders ...
In addition, the augmentation of a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor with lisdexamfetamine, a norepinephrine–dopamine releasing agent, recently failed to separate from placebo in phase III clinical trials of individuals with treatment-resistant depression, and clinical development was ...